About Us

We are the global leader in the production of pharmaceutical-grade cannabinoid APIs with unmatched licences and certifications, production capacity, industry partnerships and commercial contracts.

Unique Suite of Licences

All Brains products are inspected by and registered with the UK Ministry of Medicines & Health Products Regulatory Agency (MHRA), which certifies them for human and veterinary medicine.

Licences and Certifications

  • MHRA registration
  • GMP Certification for Human & Veterinary Medicines
  • GDP Certification
  • Schedule 1 Controlled Substances Licence

  • THC-free, 100% natural hemp derived
  • Highest purity, 100% CBD (98.0 –102.0%)
  • Consistent batch quality
  • Ethanol, preservative, flavoring-free
  • ICH-Q7 compliant 3 year reset date stability

Senior Leadership Team

The Brains management team brings unparalleled access to unique and proven investment strategies, extensive cannabis and hemp sector expertise, and M&A experience that together help establish significant competitive advantages.

Rick Brar

CEO and Chairman

Terry O'Regan


Jas Kalsi

Chief Financial Officer

Dean Billington


William Purves

Chief Commercial Officer

Barinder Bhullar

Senior VP, Corporate Affairs


Exclusive partnerships, end-to-end offerings and solutions allow Brains to expand treatment possibilities for patients worldwide.


Brains has an exclusive commercialization partnership with DSM to create CBD-based pharmaceuticals to expand treatment possibilities for patients. This partnership has enabled Brains to access multiple geographies around the world, including the UK, Brazil, Austria, the USA and Australia.

About Royal DSM: A purpose-led science-based multinational corporation active in the research, development, manufacture, marketing and sale of ingredients for the animal nutrition, human nutrition, pharmaceutical and cosmetic industries. DSM has over 21,000 employees globally, a market capitalization exceeding 30 billion Euro.​


Brains Bio has an exclusive co-branding partnership with Vitabiotics, who has 27% share of the UK vitamin and supplement market. Not only does this build market awareness for Brains and provide endorsement for the purest CBD isolate on the market, it allows seamless transition of Brains Pure CBD branded products into the retail space.

This provides a blueprint for other key markets such as Germany and USA.

Blue-Chip Companies Choose Brains